CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
In collaboration with researchers from Johns Hopkins, Akonni conducted a study with 185 M. tuberculosis isolates representing a worldwide distribution of ritampin, isoniazid, streptomycin, and ethambutol resistance genotypes. The simplified TruArray test containing 96 unique probes for 39 drug-resistant mutations in five genes enabled a single technician to run up to 24 samples in under six hours, using a thermal cycler and a microarray imager. Of 196 mutations in the culture set that were also represented on the microarray, the TruArray test correctly detected 193 (98.4 percent success rate).
In collaboration with the CDC and others, Akonni developed a TruArray test for influenza detection, subtyping, and neuramidase resistance detection from nasopharyngeal swabs. Limits of detection in clinical nasopharyngeal swab samples were about 100 RNA gene copies per test, regardless of influenza subtype. The most sensitive probes were those targeting seasonal and pandemic influenza A H275Y variants. Using a CDC surveillance and reporting guideline, definitive identification was provided for 164 of 178 samples (92 percent) and 328 of 342 hybridizations (95.9 percent). No false positives were detected.
Akonni Biosystems, 301-698-0202